Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Q1 2026 results due before market open Wednesday, May 13, with an earnings call scheduled for Thursday, May 14 at 9:30 AM ET; analysts expect EPS of ($0.03) and revenue of $0.75 million for NASDAQ:ABUS.
• In the prior quarter Arbutus reported EPS of ($0.01), beating consensus (‑$0.06), and revenue of $1.05 million versus an estimate of $0.83 million, though profitability remains weak with a negative ROE (42.39%) and net margin (‑237.88%).
• The stock carries a market cap of about $865.6M with a 52‑week range of $2.94–$5.10 and an average analyst rating of Hold (average price target $5.00); notable institutional activity includes Goldman Sachs increasing its stake by 290.3% to ~2.08M shares.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $0.75 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last issued its earnings results on Friday, March 20th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.05. Arbutus Biopharma had a negative return on equity of 42.39% and a negative net margin of 237.88%.The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $0.83 million.

Arbutus Biopharma Stock Performance

NASDAQ:ABUS opened at $4.40 on Wednesday. The stock's 50 day moving average price is $4.44 and its 200 day moving average price is $4.43. Arbutus Biopharma has a 52 week low of $2.94 and a 52 week high of $5.10. The company has a market capitalization of $865.55 million, a P/E ratio of -25.85 and a beta of 0.62.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Arbutus Biopharma in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $5.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ABUS. Goldman Sachs Group Inc. grew its stake in Arbutus Biopharma by 290.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,075,948 shares of the biopharmaceutical company's stock valued at $7,245,000 after buying an additional 1,544,070 shares during the last quarter. Legal & General Group Plc grew its stake in Arbutus Biopharma by 5.1% in the 2nd quarter. Legal & General Group Plc now owns 124,486 shares of the biopharmaceutical company's stock valued at $385,000 after buying an additional 6,089 shares during the last quarter. Rhumbline Advisers grew its stake in Arbutus Biopharma by 3.5% in the 2nd quarter. Rhumbline Advisers now owns 207,805 shares of the biopharmaceutical company's stock valued at $642,000 after buying an additional 7,048 shares during the last quarter. Prudential Financial Inc. grew its stake in shares of Arbutus Biopharma by 71.5% in the second quarter. Prudential Financial Inc. now owns 18,255 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 7,610 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Arbutus Biopharma by 29.8% in the second quarter. Invesco Ltd. now owns 181,084 shares of the biopharmaceutical company's stock worth $560,000 after acquiring an additional 41,622 shares during the last quarter. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company's pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.